(Q39885547)

15 September 2017

title

Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy (English)

1 reference

15 September 2017

0 references

Mai Miyakubo

1

1 reference

15 September 2017

Kazuto Ito

2

1 reference

15 September 2017

Takumi Yamamoto

3

1 reference

15 September 2017

Hiroyuki Takechi

4

1 reference

15 September 2017

Masaru Ohi

5

1 reference

15 September 2017

Kazuhiro Suzuki

6

1 reference

15 September 2017

publication date

12 May 2009

1 reference

International Journal of Urology

15 September 2017

published in

1 reference

15 September 2017

volume

16

1 reference

15 September 2017

issue

6

1 reference

15 September 2017

page(s)

561-565

1 reference

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02304.X

Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02304.X

The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02304.X

A receiver operating characteristic partial area index for highly sensitive diagnostic tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02304.X

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02304.X

Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02304.X

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02304.X

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02304.X

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2009.02304.X

10.1111/J.1442-2042.2009.02304.X

21 January 2018

Identifiers

DOI

1 reference

release_atybattbevdg5ee2ogtry65fl4

15 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/atybattbevdg5ee2ogtry65fl4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference